Blaze Bioscience aims to launch new pediatric brain cancer study with scorpion venom
Blaze Bioscience has scooped up $4 million of a $5 million round to maintain its momentum to hopefully initiate a Pivotal clinical study on pediatric brain cancer later this year.
Blaze is the company behind Tumor Paint, a synthetic scorpion venom that binds to cancer cells and glows under near-infrared light.
The Puget Sound Business Journal featured Blaze last year as an Innovator of the Month.
At the time, the company had raised $30 million since its founding, and Tum or Paint had been used…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Coral Garnick Source Type: news
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Health Management | Neurology | Pediatrics | Study